Using Metagenomics for Microbiome Analysis and Discovery

The past few years have seen significant growth in the use of metagenomic methods for finding and recovering metagenome-assembled genomes (MAGs). In fact, just last year the reconstruction of tens of thousands of MAGs unveiled thousands of new microbial species across several large-scale studies. Despite advances, there are ongoing debates about the quality and reliability of MAGs. This workshop will provide an overview of the generation of metagenome-assembled genomes (MAGs) looking at the pitfalls and opportunities, focusing on areas such as:

Attend this session to:

• Examination of the technical aspects of MAG generation and metagenomic analysis
• A methodological analysis of the workflows used by the EBI and other approaches that can be taken
• Quality and curation of MAGs including what they mean and what can be done with them
• How MAGs can be used to uncover novel biology, particularly from uncultured bacteria

Start Up Investor Showcase (Invite Only)

Built to connect start-up organisations in the microbiome sector with potential investors, the pre-conference investor showcase will give emerging organisations to pitch new ideas, and generate the financial momentum required to make these ideas a therapeutic or diagnostic reality.

This is your chance to present a short overview to an expert panel, and receive advice to help you generate financial momentum.

Patent Protection and the Microbiome

As such a diverse space, intellectual property considerations for the microbiome are complex, and there is no one-size-fits-all intellectual property protection strategy for all microbiome innovations. While often compared to traditional pharma and biotech industries, the scientific, regulatory, and marketing strategies for microbiome therapies tend to be different from those centred on a single small molecule or large molecule biologics. This means that when It comes to IP, protecting innovation in the microbiome world involves different considerations to the traditional pharma and biotech spaces. With microbiome therapies really coming into their own, it’s useful to approach the IP considerations of each innovation with a fresh perspective, while keeping in mind IP strategies learned from other spaces.

In this interactive workshop, you’ll have the chance to benefit from guidance from experts who have actively advised on a full-range of IP matters involving manipulation and analysis of microbiomes, and have a deep understanding of the practical and commercially relevant considerations required to develop sound IP strategies in relation to microbiome research and innovation.

Join this workshop to:

Broaden your understanding of the IP landscape to develop robust IP strategies, including IP protection, freedom to operate, licensing, opposition and litigation strategies

Understand how the approaches to describing and claiming a microbiome product or platform in a patent application may differ from those for a small or large molecule Discuss the differences between patent application and support in the USA and the EU  Look at traditional synthetic small molecules and engineered antibodies versus live biotherapeutic products comprising naturally-occurring strains or mixtures of strains

Get closer to securing meaningful patent protection for your own technology and chart a course through the patent protection shoals of your competitors Examine the challenges and opportunities for protecting and commercialising the whole spectrum of microbiome-related inventions including bacterial, FMT, gut/brain axis treatments, OTC microbiome products, prebiotics, diagnostics and AI-based microbiome analysis, formulation, manufacturing processes


Sam Minot
Staff Scientist
Fred Hutchinson Cancer Research Center

Alexandre Almeida
EBI-Sanger Postdoctoral Fellowship
European Bioinformatics Institute


Vasily Fedorin
Director of Operations
4BIO Capital

Stanislas Desjonqueres
Nexbiome Therapeutics

Sebastien Guery
Technology & Innovation Leader
DuPont Nutrition & Biosciences

Craig Thompson
HGF Limited

Mark Fitzgerald
Nixon Peabody LLP